Page last updated: 2024-08-18

quinuclidines and Cardiovascular Diseases

quinuclidines has been researched along with Cardiovascular Diseases in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R1
Brygger, L; Herrstedt, J1
Nagy, LB1
Kardos, P; Müllerová, H; Newby, DE; Román-Rodríguez, M; Singh, D; Worsley, S1
LEVIT, VG; SMULEVICH, AB1
de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U1
Doods, HN; van Zwieten, PA1

Reviews

3 review(s) available for quinuclidines and Cardiovascular Diseases

ArticleYear
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:10

    Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting

2014
[Are there cardiovascular adverse effects of inhaled anticholinergics?].
    Orvosi hetilap, 2015, Aug-02, Volume: 156, Issue:31

    Topics: Administration, Inhalation; Bronchodilator Agents; Cardiovascular Diseases; Cardiovascular System; Cholinergic Antagonists; Clinical Trials as Topic; Glycopyrrolate; Humans; Incidence; Ipratropium; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide

2015
Muscarinic receptors and drugs in cardiovascular medicine.
    Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:1

    Topics: Bradycardia; Cardiovascular Diseases; Cholinergic Agents; Endothelium, Vascular; Humans; Muscarinic Agonists; Muscarinic Antagonists; Muscle, Smooth, Vascular; Nitric Oxide; Parasympatholytics; Pirenzepine; Quinuclidines; Receptors, Muscarinic; Regression Analysis; Structure-Activity Relationship

1995

Trials

1 trial(s) available for quinuclidines and Cardiovascular Diseases

ArticleYear
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Respiratory research, 2020, Jun-05, Volume: 21, Issue:1

    Topics: Aged; Androstadienes; Benzyl Alcohols; Cardiovascular Diseases; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines

2020

Other Studies

3 other study(ies) available for quinuclidines and Cardiovascular Diseases

ArticleYear
Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    International journal of chronic obstructive pulmonary disease, 2016, Volume: 11

    Topics: Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Cardiovascular Diseases; Chlorobenzenes; Comorbidity; Drug Combinations; Evidence-Based Medicine; Humans; Lung; Muscarinic Antagonists; Patient Safety; Patient Selection; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Tiotropium Bromide; Treatment Outcome

2016
[USE OF OXYLIDINE IN THE AMBULATORY TREATMENT OF MENTAL PATIENTS].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1963, Volume: 63

    Topics: Anxiety; Anxiety Disorders; Cardiovascular Diseases; Delusions; Depression; Guilt; Humans; Hypnotics and Sedatives; Hypochondriasis; Mentally Ill Persons; Meprobamate; Neurotic Disorders; Obsessive-Compulsive Disorder; Paranoid Disorders; Phobic Disorders; Quinuclidines; Schizophrenia; Tranquilizing Agents

1963
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study.
    Drug safety, 2008, Volume: 31, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Female; Germany; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Product Surveillance, Postmarketing; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines

2008